Online inquiry

IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6652MR)

This product GTTS-WQ6652MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ITGAV gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001144999.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685
UniProt ID P06756
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6652MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7922MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ2956MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ9760MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ5488MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ1394MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ1129MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ3879MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ8196MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW